Lanean...
Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
PURPOSE: The high expense of newer, more effective adjuvant endocrine therapy agents (aromatase inhibitors [AIs]) for postmenopausal breast cancer contributes to socioeconomic disparities in breast cancer outcomes. This study compares endocrine therapy costs for breast cancer patients during the fir...
Gorde:
| Argitaratua izan da: | Springerplus |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer International Publishing
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4320689/ https://ncbi.nlm.nih.gov/pubmed/25674506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-0827-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|